DaltonTx has launched its AI-driven drug discovery platform, Dalton, aimed at streamlining the entire drug development process.
The UK-based start-up DaltonTx has officially introduced its platform, Dalton, which is designed to optimize drug discovery from data analysis to molecular design and decision-making. This innovative platform aims to create a "continuous learning engine" that supports both small-molecule and biologic medicines. With a team comprising former scientists from AstraZeneca, Exscientia, and the University of Oxford, DaltonTx is entering a competitive landscape dominated by established players such as Recursion Pharma and Insilico Medicine, as well as tech giants like NVIDIA and Alphabet.
A key feature of Dalton is its commitment to data privacy, ensuring that project data and models remain distinct to prevent cross-utilization in other projects. Co-founder Garry Pairaudeau emphasized the platform's role in enhancing human expertise and fostering an "organizational memory" that captures insights from both successes and failures in the drug discovery process.
In a significant partnership, contract research organization Sygnature Discovery has adopted the Dalton platform to bolster its AI capabilities. CEO Simon Hirst expressed enthusiasm about how Dalton can facilitate better decision-making earlier in the drug discovery process, ultimately aiming to reduce the number of compounds tested and accelerate the progression towards candidate selection.
This launch positions DaltonTx as a notable contender in the AI drug discovery arena, leveraging its biopharma expertise to differentiate itself through a focus on collaborative enablement rather than solely developing in-house therapies.